Faces of Digital Health

The Gulf Cooperation Council (GCC) brings together six Arab countries – Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates When one reads about the GCC countries, there’s nothing but the impression of prosperity: high investments, determination, and enthusiasm in tech-supported healthcare. The spending on healthcare by the GCC governments is on an astronomical rise. From a regionwide US$2.4 billion in 2016, it rose to more than US$30 billion in 2021 and is projected to surpass US$104 billion this year, according to a report from the UAE Ministry of Economy. In this episode, Pilar Fernandez Hermida International Go-to-Market expert with 20+ years of experience launching sales & partner ecosystem strategies, talks about the potential of the Middle East and MENA region for healthtech companies, the culture in the Middle East, how to interpret different style of communication here, what are the common entrepreneurial misconceptions, and where to find opportunities. Pilar says that the entrepreneurial spirit here is 10-times as strong as in the US, and that biotech and drug development are the next thing to watch for in the region.www.facesofdigitalhealth.comNewsletter: https://fodh.substack.com/Show notes: [00:02:00] Pilar Fernandez Hermida, an expert in healthcare market strategies, shares insights from Abu Dhabi. [00:04:00] Analysis of the healthcare infrastructure development in GCC post-pandemic. [00:08:00] The role of expats in the Middle East's healthcare transformation. [00:10:00] Public-private partnerships as key opportunities. [00:12:00] Cultural considerations for startups in the GCC. [00:14:00] Misconceptions about the Middle Eastern healthcare market. [00:18:00] Building long-term relationships in business. [00:20:00] Navigating diverse cultural communication in healthcare. [00:24:00] Comparing the entrepreneurial spirit in the Middle East with the U.S. and Europe. [00:28:00] Strategic advice for healthcare entrepreneurs targeting the GCC. [00:30:00] Importance of understanding regulations and digital maturity in MENA. [00:32:00] Future potential in biotech and digital health in the GCC. [00:36:00] The convergence of digital health and biotech.

In the last few years, we've witnessed a whirlwind of developments in the world of Digital Therapeutics (DTx) - from FDA approvals sparking optimism for the industry, to the establishment of regulatory frameworks in countries like Germany, France, and Belgium. However, in 2023, the industry faced a stark reality check, marked by the fall of some key players and healthcare systems' hesitancy towards embracing and financing these innovations. This turbulence has reshaped strategies and raised critical questions about the future of DTx.🔍 In this episode learn more about: 📊 The current state of the DTx industry in 2024,🗣️ Key debates of digital therapies industry players,🌐 Advocacy efforts pushing the boundaries for global adoption,🚀 Strategies to accelerate the integration of digital therapies worldwide.Newsletter: fodh.substack.comWebsite: www.facesofdigitalhealth.com

Patient-reported outcomes (PROs) have become increasingly integral in healthcare for assessing the effectiveness of treatments from the patient's perspective. It sounds like a reasonable step in improving clinical research and care provision, but gathering data can be more difficult then you may think. It isn't easy to get to marginalized communities. There are language barriers in collecting data. There are cultural aspects that impact responses. So, how can you design useful electronic solutions for patient-reported outcomes? Hear from Mustafa Ali Syed, Researcher at the Manchester Academic Health Science Centre, The University of Manchester, and Ben James, Co-founder/Chief Design Officer at uMotif - ePRO, an engagement platform designed to power clinical and real-world research. Both are co-authors of a recently published paper titled Exploring the Cross-cultural Acceptability of Digital Tools for Pain Self-reporting.www.facesofdigitalhealth.comNewsletter: https://fodh.substack.com/Show notes: 00:00:00 Why Do PROs Matter?00:04:00 Evolution of Data Collection00:06:00 Importance of Diversity in Clinical Trials00:08:00 Ethnicity, Culture, and Pain Perception00:12:00 The Role of Technology in PROs00:14:00 Designing Inclusive Digital Solutions00:20:00 Challenges in Engaging Targeted Populations00:22:00 Language and Communication Barriers00:26:00 The Future of PRO Research

Did you know that Belgium has had an idea for classifying and validating digital therapeutics since 2018? A clear framework was formed with all main stakeholders involved - from health insurance to the industry. So why are we not hearing more about DTx in Belgium? In this discussion you will hear from Dr. Steven Vandeput -  he is the Advisor for Digital MedTech and Services & Technologies Home Assistance in Belgium; he is managing the mHealthBelgium portal and, since 2019, has been a representative for beMedTech, the sector federation that represents the industry of medical technologies in Belgium. Website: www.facesofdigitalhealth.comNewsletter: https://fodh.substack.com/Show notes: 00:00 - Introduction01:45 - Digital Therapeutics in Belgium03:50 - Belgium's Healthcare Framework Development06:00 - The Validation Pyramid and Reimbursement System08:00 - Fate of Pilot Projects and Their Impact10:00 - Utilization of mHealth Belgium Portal12:00 - Challenges in Reimbursement and Financing14:00 - Prospects for Digital Therapeutic Companies16:00 - Belgium's Approach to Financing Digital Health18:00 - Anticipations for the Digital Health Field20:00 - The Evolving European Frameworks22:00 - Impact of Political Decisions and Healthcare System Integration24:00 - The Future of mHealth Belgium Platform

The field of oncology treatments is advancing very fast with innovative therapies and approaches on the market every day. It can get very tricky to support these therapies from an IT perspective, which is what you will hear more about in this discussion. I spoke with Anish Patankar, SVP and GM of Elekta’s Oncology Software Solutions, and we discusses: How to go about the US hospital market,  Development in software for oncology treatments, Challenges in scaling healthcare IT software across markets.  Newsletter: https://fodh.substack.com/www.facesofdigitalhealth.comShow notes: [00:00:00] Introduction to Elekta[00:02:00] Elekta's Global Presence[00:04:00] US Market Focus[00:06:00] Growth in Developing Countries[00:08:00] Segmentation and Technology Adoption in the US[00:10:00] Untapped Needs and Opportunities in the US[00:12:00] Elekta's Use of AI[00:14:00] Patient Feedback and Clinical Decision Making[00:18:00] Navigating Legacy Software in Healthcare IT[00:20:00] Modernization and Customer Satisfaction[00:22:00] Global Standardization and Regulation Challenges[00:24:00] Interoperability and Open Ecosystem[00:26:00] Future of Oncology Market Development: the interplay between medications and radiation, and the potential of theranostics.[00:28:00] Exciting Technologies in Healthcare Beyond Oncology: personalized healthcare, digital twins[00:30:00] Cautions for the Future: The critical debate on the balance between innovation speed and safety, particularly with generative AI.

In 2023, Insilico Medicine—a biotech company developing medications with a heavy reliance on AI—used AI to develop an experimental drug for the incurable lung disease idiopathic pulmonary fibrosis. The treatment is in mid-stage trials in the US and China, with some results expected in early 2025.Biotech is one of the fields that has been using generative AI for years, even before ChatGPT brought the technology to public view.Latest technology is essential in drug development. However, the convergence of digital health and pharma seems less clear. Digital health apps started gaining popularity around 2015, and at that time, it seemed all pharma companies were trying to figure out what they could gain from apps, so they financed accelerators and incubators one after the other.We've seen many ideas about how Pharma should or could use digital health.In the last few years, there have been many notorious cases when partnerships failed—a seemingly unicorn, Proteus, which designed digital sensors-equipped pills, went bankrupt in 2019 after Otsuka Pharmaceuticals pulled out of a funding round. Pear Therapeutics, the guiding star in the DTx space and the leader in FDA-cleared prescription digital therapeutics, partnered with Novartis, but in the end, the company filed for bankruptcy in 2023. So where is Pharma in relation to digital health and digital therapeutics? In this episode, Amir Lahav shares his thoughts about the impact of AI on biotech, the state of decentralized clinical trials, and the potential of technology for improved drug development, clinical trials, and patient responses.Newsletter: https://fodh.substack.com/www.facesofdigitalhealth.comShow notes:[00:02:00] The Convergence of Digital Health and Pharma Discussion on the role of digital health apps in pharmaceuticals. The rise and fall of pharma and tech company partnerships, with examples like Proteus and Peer Therapeutics. [00:06:00] AI Trends in Biotech and Pharma[00:08:00] Enhancing Clinical Trials with AI and continuous patient monitoring[00:10:00] The Importance of Data in Clinical Trials[00:12:00] The Reality of Oncology Trials and Endpoints[00:14:00] Quality of Life in Medicine as the Endpoint[00:16:00] The Rise of Decentralized Clinical Trials[00:18:00] Pharma's Evolving Digital Health Strategies[00:22:00] Impact on Digital Health Industry[00:24:00] Collaboration and Sharing Knowledge in the Pharma Industry [00:26:00] The need for long-term investment and strategic piloting of digital health solutions [00:28:00] What Inspires in Pharma and Biotech in Personalized Treatments [00:30:00] The State of Precision Medicine and Targeted Therapies[00:34:00] The Role of Pharmacogenomics[00:36:00] Anticipations for 2024 and Beyond

HLTH (https://hlth.com/) is an event where you will see a literal forest on one of the stages, be able to take a selfie with a unicorn mascot, and get perks like hlth branded pink nail polist on your entrance. In the last few years, HLTH has become the most flashy, visible and must-go digital health event in the US.In this episode, Richard Scarfo, president of HLTH, talks about HLTH's approach to making events memorable, why HLTH is taking experience economy as a guiding principle in the investment in the scene at HLTH. You will also hear networking tips, and why HLTH is coming to Europe in June 2024. HLTH Europe (17-20 June 2024): https://europe.hlth.com/www.facesofdigitalhealth.comNewsletter: https://fodh.substack.com/

Migraine is 3 times more common in women than in men. 2/3 of patients with Alzheimer’s disease.Gender differences are real and they matter. The Women's Brain Project (WBP) is a Swiss-based international non-profit organization founded in 2016. It comprises a diverse team of academic and social scientists, medical doctors, engineers, patients, caregivers, artists, and AI experts. The WBP focuses on understanding sex and gender differences in brain and mental diseases to pave the way for precision medicine. This involves tailoring medical treatment to the individual characteristics of each patient, including factors like sex, gender, genomic and proteomics, microbiome, ethnicity, and socio-economic status​​.In this episode Antonella Santuccione Chadha, medical doctor and CEO of Women’s brain project and Anna De, Head of Stakeholder Engagement at Women's Brain Project explain: where are we with data about women’s health specifics, what is driving research in women’s health, what is the negative health and societal impact on women because of their predominant role in caregiving.Show notes: [00:03:01] Antonella Discusses Women's Brain Project: The gaps in medicine for not considering sex and gender. The transformation from an association to a foundation. The need for commitment and support for evidence generation. [00:05:20] Underrepresentation of Women in Research: Antonella explains historical exclusion of women and the current need for inclusion. Addressing biases and the importance of female leadership in medicine. [00:08:23] Evaluating Existing and New Treatments:The role of real-world data in addressing the gap in gender responses to treatments.[00:11:27] Key Findings and Successes:Antonella passes the conversation to Anna to discuss policy successes.[00:11:59] Anna Discusses Policy Impact: How Women's Brain Project informs global policy. Collaboration with large organizations and efforts to influence policy. [00:16:01] Migraine Research and Campaigns:Details on the migraine awareness campaign and insights on how it impacts women specifically.[00:19:30] Antonella on Scientific Evidence: The role of female hormones in migraines and other diseases. The importance of translating science into political measures. [00:20:38] Alzheimer's Disease in Women:Discussion on why two-thirds of Alzheimer's patients are women and associated factors.[00:26:00] Relationship Between Research and Medical Practice: Antonella shares her experiences as a clinician and the realization of gender disparities in her patients. The importance of educating healthcare professionals on sex and gender differences. [00:29:03] Anna Adds to the Discussion: The need to consider both sex and gender differences in healthcare. The societal impact of caregiver burden on women. [00:33:34] Identifying Questions and Approaches for Research:The conversation turns to the complexities of starting research with the right questions and data.[00:37:18] Key Changes Needed to Advance Women's Health:Antonella and Anna discuss the three key changes they hope to see: investment in women-driven innovation, prioritizing sex and gender differences in policy agendas, and empowering women with knowledge about their health.[00:41:34] Closing Remarks: The need for more research and better patient management, especially regarding menopause. The call for the younger female generation to lead change. Newsletter: https://fodh.substack.com/www.facesofdigitalhealth.com

Laboratory tests provide doctors with crucial information for diagnosis, monitoring disease progression, evaluating organ function, assessing risk factors for diseases and more. Laboratory testing can be reassuring, however, it is often deemed unnecessary. In this short episode recorded at HLTH, we’re going to talk about laboratory test optimization. How can it be done without undermining clinical autonomy, what kind of real-time insights can be offered to doctors with tech and more. You will hear from Pam Stahl, President of of Avalon Healthcare Solutions - American Lab Insights Company, that help payers and providers optimize treatments, improve outcomes, and drive down overall cost.Newsletter: https://fodh.substack.com/www.facesofdigitalhealth.comShow notes: [00:02:04] - Introduction to Avalon Health Solutions and their role in generating actionable insights from lab results.[00:02:21] - Discussion on the big picture problem in healthcare: the overuse and underuse of lab tests and the drive towards improving clinical decision-making.[00:03:25] - Clarification on Avalon's approach to managing unnecessary tests and their non-involvement in claims adjudication.[00:03:49] - Explanation of how Avalon provides guidance on appropriate test ordering and interpretation based on evidence-based medicine.[00:04:20] - The learning curve for providers in test ordering and the issue of test misuse.[00:05:16] - Areas where lab tests are often underutilized, particularly in cancer diagnosis.[00:05:45] - The potential of using lab data predictively, with a focus on chronic kidney disease.[00:06:20] - How Avalon creates patient profiles and uses predictive analytics to improve healthcare management.[00:06:53] - Avalon's ongoing development of predictive models and their impact on healthcare.[00:07:36] - The challenge of changing the status quo in lab test utilization and the cost savings involved.[00:07:47] - Avalon's growth and the scale of their operations, with a client base of 33 million members.[00:08:00] - The role of patient engagement and communication strategies in healthcare management.[00:08:41] - The importance of accurate and clear communication channels with patients to avoid confusion.[00:09:08] - The rapidly evolving field of genetic testing and Avalon's role in managing the abundance of available tests.[00:10:07] - Addressing concerns about over-systemizing lab test ordering and the potential for provider friction.[00:11:13] - Feedback from clinicians and Avalon's clinical advisory board on the impact of their services.[00:11:55] - The broader implications of cost savings and sustainability in healthcare through better lab test management.[00:12:11] - In-depth look at predictive analytics and its application in healthcare outcome improvements.[00:13:18] - Strategies for Avalon's customer expansion and managing growth.

In this episode, you’re going hear about the German market for digital health startups, the innovation approach at Charite, one of Europe's largest university hospitals, the challenges with digital therapeutics in Germany and beyond. I spoke with Dorothée Marie-Louise Döpfer,Deputy Head of Digital Labs and program Manager of the Digital Health Accelerator & Community Building at Charite UMC Berlin. Dorothee also shared her expectations about the impact of AI on European health systems. Newsletter: https://fodh.substack.com/www.facesofdigitalhealth.com